Cidara therapeutics, inc. (CDTX)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer

2,530

-

19,100

-

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Operating expenses:
Research and development

12,996

11,490

11,499

10,743

12,669

13,046

11,278

11,619

13,199

10,230

9,159

13,191

10,243

11,310

8,729

8,471

7,189

7,564

6,766

4,210

4,935

3,474

1,992

966

278

Cost of in-process research and development acquired

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,607

-

General and administrative

4,095

4,405

4,573

3,525

3,735

3,552

3,447

3,533

3,611

3,229

3,090

3,424

3,155

3,043

3,607

3,391

2,696

2,364

2,441

2,236

1,797

1,175

1,328

522

281

Total operating expenses

17,091

15,895

16,072

14,268

16,404

16,598

14,725

15,152

16,810

13,459

12,249

16,615

13,398

14,353

12,336

11,862

9,885

9,928

9,207

6,446

6,732

4,649

3,320

3,095

559

Loss from operations

-14,561

-14,080

3,028

-14,268

-16,404

-16,598

-14,725

-15,152

-16,810

-13,459

-12,249

-16,615

-13,398

-14,353

-12,336

-11,862

-9,885

-9,928

-9,207

-6,446

-6,732

-4,649

-3,320

-3,095

-559

Other income (expense):
Gain (Loss) on Derivative Instruments, Net, Pretax

0

-11

0

681

-270

4,124

888

-1,112

0

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Interest income, net

22

57

11

40

113

182

222

164

61

31

-8

-30

0

-41

109

107

96

60

33

32

-5

0

1

-44

-45

Other expense

-

-

-

0

-

-

-

206

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of convertible notes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-80

-103

Total other income (expense)

-

-

0

721

-

5,366

-4

-1,154

61

31

-8

-30

0

-41

109

107

96

-

33

-

-

-

-

-

-

Total other income (expense)

22

-

11

-

-157

-

1,106

-

-

-

-

-

-

-

-

-

-

-

-

32

-5

-

1

-124

-148

Net loss and comprehensive loss

-14,539

-14,023

3,039

-13,547

-16,561

-12,342

-13,619

-16,306

-16,749

-13,428

-12,257

-16,645

-13,398

-14,394

-12,227

-11,755

-9,789

-9,868

-9,174

-6,414

-6,737

-4,649

-3,319

-3,219

-707

Allocation of earnings to participating securities

-

-

444

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Recognition of beneficial conversion feature

2,762

0

0

0

0

-

0

10,329

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss attributable to common shareholders

-17,301

-13,579

2,595

-13,547

-16,561

-

-13,619

-26,635

-

-

-12,257

-16,645

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic earnings (loss) per common share (in dollars per share)

-0.46

-

0.08

-

-0.58

-

-0.49

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Diluted earnings (loss) per common share (in dollars per share)

-

-

0.08

-

-

-

-0.49

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Shares used to compute basic net income (loss) per share (in shares)

37,856

-

33,006

-

28,532

-

27,705

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Weighted Average Number of Shares Outstanding, Diluted

-

-

38,687

-

-

-

27,705

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted net loss per common share (USD per share)

-

-

-

-0.49

-

-

-

-1.13

-0.80

-0.66

-0.73

-0.99

-0.80

-0.88

-0.88

-0.85

-0.71

3.93

-0.67

-0.59

-5.92

-4.68

-2.98

-5.04

-1.81

Shares used to compute basic and diluted net loss per common share (in shares)

-

-

-

27,786

-

-

-

23,592

20,894

19,511

16,864

16,831

16,795

16,366

13,910

13,871

13,807

13,910

13,674

10,957

1,138

1,137

1,113

638

389

Net Income (Loss) Attributable to Parent

-14,539

-14,023

3,039

-13,547

-16,561

-12,342

-13,619

-16,306

-16,749

-

-12,257

-16,645

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain on short-term investments

-

-

0

-

-

-

2

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax

-

-

-

0

-

-

-

15

-10

-

-1

4

-3

16

-13

-2

6

-

-5

-

-

-

-

-

-

Comprehensive loss

-

-

3,039

-13,547

-

-12,341

-13,617

-16,291

-16,759

-13,435

-12,258

-16,641

-13,401

-14,378

-12,240

-11,757

-9,783

-9,871

-9,179

-6,414

-6,737

-

-3,319

-

-